BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Higazi AA, El-Haj M, Melhem A, Horani A, Pappo O, Alvarez CE, Muhanna N, Friedman SL, Safadi R. Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis. Clin Exp Immunol 2008;152:163-73. [PMID: 18279442 DOI: 10.1111/j.1365-2249.2008.03606.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Şimşek Ş, Çetin İ, Çim A, Kaya S. Elevated levels of tissue plasminogen activator and E-selectin in male children with autism spectrum disorder: t-PA and selectin levels in ASD. Autism Research 2016;9:1241-7. [DOI: 10.1002/aur.1638] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 González-Miguel J, Valero MA, Reguera-Gomez M, Mas-Bargues C, Bargues MD, Simón F, Mas-Coma S. Numerous Fasciola plasminogen-binding proteins may underlie blood-brain barrier leakage and explain neurological disorder complexity and heterogeneity in the acute and chronic phases of human fascioliasis. Parasitology 2019;146:284-98. [PMID: 30246668 DOI: 10.1017/S0031182018001464] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
3 Gur-wahnon D, Mizrachi T, Wald-altman S, Higazi AA, Brenner T. Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential. Journal of Autoimmunity 2014;52:36-43. [DOI: 10.1016/j.jaut.2013.12.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Sereda MJ, Bradding P, Vial C. Adenosine potentiates human lung mast cell tissue plasminogen activator activity. J Immunol 2011;186:1209-17. [PMID: 21149610 DOI: 10.4049/jimmunol.1001563] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
5 Tuomi H, Kultti J, Danielsson J, Kangastupa P, Åkerman K, Niemelä O. Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use: Immune activation in alcoholics. J Gastroenterol Hepatol 2014;29:1991-5. [DOI: 10.1111/jgh.12639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lin L, Jin Y, Mars WM, Reeves WB, Hu K. Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-κB pathways. Am J Pathol 2014;184:2757-67. [PMID: 25131752 DOI: 10.1016/j.ajpath.2014.06.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
7 Garnæs E, Mortensen C, Hobolth L, Andersen O, Nehlin J, Møller S. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. PLoS One 2019;14:e0220697. [PMID: 31465463 DOI: 10.1371/journal.pone.0220697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol. 2012;46:334-338. [PMID: 21934527 DOI: 10.1097/mcg.0b013e31822da19d] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
9 Lin L, Jin Y, Hu K. Tissue-type plasminogen activator (tPA) promotes M1 macrophage survival through p90 ribosomal S6 kinase (RSK) and p38 mitogen-activated protein kinase (MAPK) pathway. J Biol Chem 2015;290:7910-7. [PMID: 25670857 DOI: 10.1074/jbc.M114.599688] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
10 Cezar R, Desigaud D, Pastore M, Kundura L, Dupuy AM, Cognot C, Vincent T, Reynes C, Sabatier R, Maggia E, Corbeau P. Insulin resistance is linked to a specific profile of immune activation in human subjects. Sci Rep 2021;11:12314. [PMID: 34112902 DOI: 10.1038/s41598-021-91758-3] [Reference Citation Analysis]
11 Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. The intriguing role of soluble urokinase receptor in inflammatory diseases. Critical Reviews in Clinical Laboratory Sciences 2016;54:117-33. [DOI: 10.1080/10408363.2016.1269310] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
12 Kang LI, Isse K, Koral K, Bowen WC, Muratoglu S, Strickland DK, Michalopoulos GK, Mars WM. Tissue-type plasminogen activator suppresses activated stellate cells through low-density lipoprotein receptor-related protein 1. Lab Invest 2015;95:1117-29. [PMID: 26237273 DOI: 10.1038/labinvest.2015.94] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
13 Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32:500-509. [PMID: 22098627 DOI: 10.1111/j.1478-3231.2011.02665.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lin L, Hu K. Tissue-type plasminogen activator modulates macrophage M2 to M1 phenotypic change through annexin A2-mediated NF-κB pathway. Oncotarget 2017;8:88094-103. [PMID: 29152144 DOI: 10.18632/oncotarget.21510] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
15 Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol 2012;23:1329-38. [PMID: 22677557 DOI: 10.1681/ASN.2011111123] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
16 White S, Lin L, Hu K. NF-κB and tPA Signaling in Kidney and Other Diseases. Cells 2020;9:E1348. [PMID: 32485860 DOI: 10.3390/cells9061348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]